SOLV
Solventum
$83.49
▲ 0.6%Updated Aug 7, 11:30 AM ET
SOLV at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 65/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 3.9% over the last 12 months
Market Cap
$13.55B
P/E
10.14x
Forward P/E (est.)
7.24x
ROE
30.7%
Revenue Growth
-0.6%
EPS Growth
276.2%
Profit Margin
17.3%
FCF Yield
—
Debt / Equity
1x
ROIC
17.0%
Interest Coverage
—
Current Ratio
1.07x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
65/100
Solventum (SOLV) is a large-cap company in the Health Care Technology industry, part of the Health Care sector of the S&P 500, with a market value around $13.55B.
In its latest reported year it generated about $8.32B in revenue and $1.56B in net profit.
Our model rates SOLV Favorable (65/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what SOLV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. SOLV trades near $83.49, above its 50-day average ($74.86) and 200-day average ($74.56). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 47 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. SOLV's is $2.27 (~2.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month SOLV found buyers near $73.04 (support) and sellers near $83.42 (resistance); its 52-week range is $62.38–$88.20. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
3Y CAGR
0.8%
Revenue moved from $8.13B in 2022 to $8.32B in 2025, a 0.8% compound annual growth rate. The most recent year declined 0.6% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
53.5%
Operating Margin
26.2%
Net Margin
18.7%
ROE
30.7%
Solventum keeps about 17.3% of each sales dollar as net profit, with a 53.5% gross margin and 26.2% operating margin. Return on equity is 30.7% and return on invested capital about 17.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$5.04B
Net Debt
$4.47B
Net Debt / EBITDA
2.05x
Debt / Equity
1x
Leverage: debt-to-equity is 1.0x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $5.04B of total debt against $561.00M of cash.
Operating CF
$369.00M
Free Cash Flow
-$10.00M
FCF Margin
-0.1%
In the latest year Solventum produced about $369.00M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
10.14x
P/S
1.6x
P/B
2.97x
EV / EBITDA
—
SOLV trades at 10.1x trailing earnings (about 7.2x on estimated forward earnings), 1.6x sales, and 3.0x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Where SOLV sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How SOLV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), SOLV ranks #20 of 324 by our overall rating. It trades at a discount versus the sector on earnings (10.1x P/E vs. 27.3x median) with a higher return on equity (30.7% vs. 14.1%) and slower revenue growth (-0.6% vs. 7.6%).
P/E vs sector
10.1x
median 27.3x
ROE vs sector
30.7%
median 14.1%
Growth vs sector
-0.6%
median 7.6%
Sector rank
#20
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $83.49 today · expected CAGR -4% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $8.57B | $8.83B | $9.10B | $9.37B | $9.65B |
| Net income | $1.63B | $1.68B | $1.73B | $1.78B | $1.83B |
| EPS | $10.04 | $10.34 | $10.65 | $10.97 | $11.29 |
| Share price (low) | $60.21 | $62.02 | $63.88 | $65.79 | $67.77 |
| Share price (high) | $100.35 | $103.36 | $106.46 | $109.66 | $112.95 |
| CAGR (low–high) | -28% / 20% | -14% / 11% | -9% / 8% | -6% / 7% | -4% / 6% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for SOLV:
- High net margins (17.3%) point to pricing power or efficiency.
- Strong return on equity (30.7%) shows capital is put to work well.
- Our model's overall read is Favorable (65/100).
The case against SOLV:
- Revenue growth is slow/negative (-0.6%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (-0.6%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Solventum is a large-cap health care business with shrinking revenue, with solid profitability, and a heavier debt load to watch. It trades at 10.1x earnings, which our model scores Favorable (65/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 22 Wall Street analysts covering SOLV recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+7 pts of buy ratings).
Latest SEC Filings
SOLV's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
SOLV — frequently asked questions
Is SOLV a good stock to buy?
We don't give buy or sell advice. Our model rates Solventum Favorable (65/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is SOLV's rating on The Stocks School?
Solventum currently scores 65/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does SOLV's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Solventum's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for SOLV calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this SOLV analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell SOLV. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.